Literature DB >> 22449201

Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.

D Monti1, U Herranz, L Dal Bo, A Subissi.   

Abstract

BACKGROUND: In a previous study a new hydrosoluble nail lacquer (P-3051) containing 8% ciclopirox (CPX) showed higher nail penetration compared to a water-insoluble 5% amorolfine (MRF) lacquer. To our knowledge, in vivo human data on a similar topic are not available.
OBJECTIVES: To compare fingernail penetration of P-3051 with that of MRF reference in humans and to evaluate their predicted efficacy against Trichophyton rubrum and Candida parapsilosis.
METHODS: Single centre, randomized, multiple dose, open label, within subjects study. Test and reference were self-applied to all fingernails of either hand for 28 days. At baseline and after 15 and 25 days, the nail free edge was collected for analysis. Efficiency coefficients were calculated for T. rubrum and C. parapsilosis as ratios of nail concentration/minimum inhibitory concentration. The coefficients were classified as very high, high or poor.
RESULTS: Nail concentrations after 15 days were 2.82 ± 0.58 μg/mg for CPX and 0.64 ± 0.11 μg/mg for MRF. At day 25 there was a non-significant decline (1.85 ± 0.31 μg/mg, P = 0.077) for CPX and a highly significant (0.13 ± 0.03 μg/mg, P = 0.0002) 80% decline for MRF. Efficiency coefficients were very high/high in all subjects treated with P-3051 against both T. rubrum and C. parapsilosis; they were significantly lower for MRF reference against both pathogens at both observation points.
CONCLUSIONS: P-3051 exhibited better penetration and higher predicted efficacy after in vivo multiple application to human fingernails when compared to MRF reference. These in vivo data are in good agreement with our previous in vitro study.
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449201     DOI: 10.1111/j.1468-3083.2012.04529.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

1.  In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.

Authors:  Natsuki Kubota-Ishida; Naomi Takei-Masuda; Kaori Kaneda; Yu Nagira; Tsubasa Chikada; Masahiro Nomoto; Yuji Tabata; Sho Takahata; Kazunori Maebashi; Xiaoying Hui; Howard I Maibach
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  [Onychomycosis : a crown jewel of dermatology].

Authors:  H-J Tietz; P Nenoff
Journal:  Hautarzt       Date:  2012-11       Impact factor: 0.751

Review 3.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

4.  Ciclopirox 8% HPCH Nail Lacquer in the Treatment of Mild-to-Moderate Onychomycosis: A Randomized, Double-Blind Amorolfine Controlled Study Using a Blinded Evaluator.

Authors:  Matilde Iorizzo; Ilona Hartmane; Andra Derveniece; Ingmars Mikazans
Journal:  Skin Appendage Disord       Date:  2015-11-07

5.  Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.

Authors:  Daniela Monti; Silvia Tampucci; Valentina Paganini; Susi Burgalassi; Patrizia Chetoni; Jordi Galván; Francesco Celandroni; Emilia Ghelardi
Journal:  Life (Basel)       Date:  2022-05-27

Review 6.  Amorolfine vs. ciclopirox - lacquers for the treatment of onychomycosis.

Authors:  Katarzyna Tabara; Anna E Szewczyk; Wojciech Bienias; Agnieszka Wojciechowska; Marta Pastuszka; Magdalena Oszukowska; Andrzej Kaszuba
Journal:  Postepy Dermatol Alergol       Date:  2015-02-03       Impact factor: 1.837

Review 7.  Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis.

Authors:  Bianca Maria Piraccini; Matilde Iorizzo; André Lencastre; Pietro Nenoff; Dimitris Rigopoulos
Journal:  Dermatol Ther (Heidelb)       Date:  2020-07-23

Review 8.  Updated Perspectives on the Diagnosis and Management of Onychomycosis.

Authors:  Julianne M Falotico; Shari R Lipner
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.